Last edition
News about "Merck SciBrunch Therapeutics deal"
Merck Licenses SciBrunch's KRAS G12D Inhibitor
Merck enters into exclusive global license agreement with SciBrunch Therapeutics for SPR2015, an investigational oral KRAS G12D (ON) inhibitor.
Merck SciBrunch Therapeutics Deal | 29/09/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members